Blockchain Registration Transaction Record

Greenland Mines Secures Canadian Patent for Klotho Gene Therapies Targeting Neurodegenerative Diseases

Greenland Mines (GRML) announces Canadian patent for Klotho-based gene therapies targeting Alzheimer's, Parkinson's, ALS. KLTO-202 advances to GMP manufacturing. Learn more at MissionIR.

This patent strengthens Greenland Mines' position in the rapidly growing gene therapy market, particularly for Alzheimer’s, Parkinson’s, and ALS. For investors, it signals potential revenue streams from a diversified biotech pipeline alongside mining operations. For patients and caregivers, it offers hope for new treatments targeting memory and cognition. The advancement of KLTO-202 to GMP manufacturing and upcoming regulatory interactions could accelerate clinical development, making this a pivotal moment for the company and the neurodegenerative disease landscape.